VTGN Stock Summary and Trading Ideas (Vistagen Therapeutics | NASDAQ:VTGN)

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Vistagen Therapeutics trades on the NASDAQ stock market under the symbol VTGN.

As of February 13, 2026, VTGN stock price declined to $0.51 with 3,014,510 million shares trading.

VTGN has a beta of 0.60, meaning it tends to be less sensitive to market movements. VTGN has a correlation of 0.00 to the broad based SPY ETF.

VTGN has a market cap of $19.97 million. This is considered a Sub-Micro Cap stock.

Last quarter Vistagen Therapeutics reported $303,000 in Revenue and -$.45 earnings per share. This beat revenue expectation by $46,480 and missed earnings estimates by -$.06.

In the last 3 years, VTGN traded as high as $24.71 and as low as $.43.

The top ETF exchange traded funds that VTGN belongs to (by Net Assets): VTI, VXF, PSIL, IWC, DFAS.

VTGN has underperformed the market in the last year with a price return of -82.3% while the SPY ETF gained +13.0%. VTGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -86.7% and -9.4%, respectively, while the SPY returned +1.7% and -1.5%, respectively.

VTGN support price is $.52 and resistance is $.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTGN shares will trade within this expected range on the day.